EGFR and breast carcinoma: Initially, Bissell discovered that FAM83A is overexpressed in breast cancer, which can lead to EGFR-TKI resistance and promote tumorigenesis by interacting with c-RAF and PI3K p85 (Lee et al., 2012), and in the same year, Jackson Laboratories identified FAM83B as an oncogenic transformation driven by EGFR-RAS-MAPK mediators (Cipriano et al., 2012).